ClinicalTrials.gg
CompletedNCT02440841Updated Jul 30, 2015

Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon

A Phase 1 interventional study of fedovapagon and Itraconazole in Nocturia, sponsored by Vantia Ltd. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-30.

Sponsored by Vantia Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Nocturia by Vantia Ltd — none open to participants now, none under way, none of them phase 3. Nocturia · Vantia Ltd.

Enrollment
6th of 10
29 · median 30
Started
2015
with 1 other
Phase 1
6 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Nocturia by Vantia Ltd, this one is the 6th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 1, and was the 8th registered.

Nocturia

134 studies on the registry are indexed under Nocturia; 22 are open to participants now.

Browse Nocturia studies →

Open to participants now

None of the 10 studies in Nocturia by Vantia Ltd is open now. The open studies under Nocturia, anywhere →

Who these studies take

Of the 17 Nocturia studies recruiting now, 13 (76%) set no upper age limit and 2 (12%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Nocturia by Vantia Ltd as a file.
02

Study summary

The purpose of this study is to investigate the potential for co-administration of strong inhibitors or inducers of CYP3A4 to alter the pharmacokinetics of fedovapagon.

Read the detailed description

Fedovapagon is a vasopressin V2 receptor agonist in development for the treatment of nocturia. Agonism of the V2 receptor, located in the collecting ducts of the kidney, leads to translocation of aquaporin channels and increased re absorption of water and anti-diuresis.

A number of drugs that are commonly co-prescribed in the population who may present for treatment of nocturia are inhibitors of CYP3A4, including diltiazem, verapamil, erythromycin and clarithromycin and may therefore impact the plasma levels of fedovapagon if co administered.

Conversely, concomitant intake of drugs that are potent CYP3A4 inducers may lead to lower than anticipated plasma concentrations of fedovapagon thus reducing the efficacy of fedovapagon. It is therefore important to assess the effect of CYP3A4 induction on the pharmacokinetic (PK) parameters of fedovapagon.

The study design uses itraconazole as a potent inhibitor of CYP3A4 and, in a separate cohort of subjects, rifampicin as a potent CYP3A4 inducer at doses intended to maximize the potential to demonstrate an interaction.

03

Conditions studied

  • Nocturia

Browse trials for

Keywords

  • VA106483
  • fedovapagon
  • drug-drug interaction
  • DDI
  • males
  • rifampicin
  • rifampin
  • itraconazole
  • CYP3A4
  • pharmacokinetics
  • PK
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy males aged 18 to 45
  • Have a between 18 and 29.9 kg/m2 (weight: ≥50 kg and ≤100 kg)
  • No medical history
  • Ability to comply with the requirements of the study
  • Provide written
  • (AST) and alanine aminotransferase (ALT) should be below or equal to upper level of normal (). Otherwise liver enzymes should show no clinical significant abnormalities. Total should not exceed 1.5 x ULN. Liver enzymes will be re-tested only once before randomization if required.
  • Be judged by the Investigator to be in good health based on medical history (in particular, no congestive heart failure, ischemic heart disease, valvular heart disease, significant pulmonary disease, renal failure, edematous disorder, liver disease, gastric disorders, porphyria, diabetes mellitus or hereditary disorders of carbohydrate metabolism), physical examination, vital sign measurements and laboratory safety tests
  • Agree to refrain from the consumption of grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts, mustard) and charbroiled meats containing products beginning 1 week prior to administration of the initial administration of trial drug, throughout the trial
  • Use of any prescribed medication or St John's Wort within 14 days (or 5 half-lives if this is longer) or over-the-counter medication (except paracetamol) within 1 week of dosing. Specific medication not to be taken within 2 weeks of (before or after) administration of itraconazole is described in the Summary of Product Characteristic for Sempera®
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    fedovapagon and itraconazole

    Two daily doses of fedovapagon and once daily doses of itraconazole

    Drug: fedovapagon · Drug: Itraconazole

  • Experimental
    fedovapagon and rifampicin

    Two daily doses of fedovapagon and once daily doses of rifampicin

    Drug: fedovapagon · Drug: rifampicin

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma fedovapagon concentration in presence and absence of co-administered itraconazole or rifampicin

    Time frame: 10-12 days

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: 10-12 days

  2. Area under the plasma concentration curve versus time curve with extrapolation to infinity (AUC(0-infinity))

    Time frame: 10-12 days

  3. Number and type of adverse events

    Time frame: 12-14 days

  4. Change from baseline in 12-lead ECG

    Time frame: 12-14 days

  5. Change from baseline in vital signs and physical examination

    Time frame: 12-14 days

  6. Change from baseline in laboratory assessments

    Time frame: 12-14 days

07

Study locations

1 site
  • PAREXEL Early Phase Clinical Unit Berlin
    Berlin, 14050, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2015
First posted
May 12, 2015
Start
May 2015
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Jul 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02440841
Lead sponsor
Vantia Ltd
Responsible party
Sponsor
First posted
May 12, 2015
Start date
May 2015
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Jul 30, 2015

Study contacts

Tshibuabua Kabasela
study director · Parexel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fedovapagon · Itraconazole · Rifampin

Start the discussion